Lunit

Lunit FCF/Debt

The Free Cash Flow to Debt Ratio of Lunit (328130.KQ) as of Oct 17, 2026 is -27.47 %. In the previous year, Free Cash Flow to Debt Ratio was -61.66 % — a change of -55.45% (higher).

FCF/Debt

-27.47 %

YoY

-55.45%

Last updated:

Free Cash Flow to Debt Ratio of Lunit is 2024 -27.47 % . Free Cash Flow to Debt Ratio of Lunit was 2023 -61.66 % . It decreases by -55.45% higher compared to the previous year.

The Lunit FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2020
-54.53 KRW
Jan 1, 2021
-3,562.97 KRW
Jan 1, 2022
-49.32 KRW
Jan 1, 2023
-61.66 KRW
Jan 1, 2024
-27.47 KRW
The Lunit FCF/Debt history
YEARFCF/DebtYoY
-27.47 %-55.45%
-61.66 %+25.01%
-49.32 %-98.62%
-3,562.97 %+6,434.24%
-54.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Lunit Stock analysis

What does Lunit do? Lunit Inc is a South Korean company headquartered in Seoul, operating within the Health Care sector. The company has 293 employees and went public on July 21, 2022, with its ticker listed as 328130.KQ and ISIN KR7328130000. Lunit provides software solutions for medical diagnostic imaging services, focusing on the development and supply of AI-powered medical software. Its offerings include cancer diagnostic aid solutions, cancer early detection solutions, and cancer risk prediction solutions. The company's technology leverages artificial intelligence to enhance diagnostic capabilities in healthcare settings. Lunit's website is www.lunit.io, where further information about its services and solutions can be accessed. The company operates in the Health Care industry, specifically targeting medical imaging and AI-driven diagnostic tools. As of the latest available data, Lunit is engaged in the development and commercialization of AI-based medical software, aiming to improve the accuracy and efficiency of cancer-related diagnostics. The firm's IPO date marks its transition to a publicly traded company, reflecting its growth and market position in the healthcare technology space. Lunit's focus on AI applications in medical imaging positions it as a key player in the digital health sector, particularly within the Korean market and beyond. The company's solutions are designed to support healthcare professionals in making more informed diagnostic decisions, potentially reducing the time and resources required for cancer detection and treatment planning. Lunit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lunit stock

Free Cash Flow to Debt Ratio of Lunit is -27.47 % in 2024.

Free Cash Flow to Debt Ratio of Lunit changed from -61.66 % to -27.47 %, representing a -55.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Lunit since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Lunit with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Lunit

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Lunit